Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Anne Ortved Gang, MD

The aim of the project is to clarify whether DLBCL exhibits mutational diversity among different lymph node tumors in one and the same patient. It is desired to find out whether a possible difference between lymph node tumors / tumors can explain why patients who initially (at diagnosis) have the same prognosis, sometimes have a completely different course, eg with rapid recurrence of the disease after treatment.

A possible difference could also perhaps shed light on why disease in specific places spreads more frequently to the brain - and therefore have an impact on when one chooses to give preventive treatment against spread to the brain.

Monitoring of circulating cell-free DNA (ctDNA) is a new, potential, non-invasive tool for measuring the full spectrum of genetic variations / mutations and is to be investigated in our study as a possible non-invasive assessment of diversity / heterogeneity.

Only about 60% of patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard chemo- and immunotherapy, with R-CHOP(Rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, prednisone).

Early and more accurate identification of patients with unfavorable prognosis after R-CHOP will enable the clinician to find patients who need other treatment strategies. New predictive biomarkers are needed to predict the effect of treatment at the individual level.

A proportion of patients have, or develop, lymphoma involvement of the central nervous system (CNS) and this group has a particularly dismal outcome. Identification of patients with primary subclinical or later manifest involvement of the CNS also requires new and improved diagnostic methods. Currently, a number of clinical parameters are included in a CNS-IPI risk score, that can be used to predict the risk of CNS disease. This score enables the clinicians to decide if patients should have prophylactic chemotherapy to prevent development of CNS disease. However, this risk model is far from accurate and the effect of prophylactic treatment is based on a low level of evidence.

DLBCL is a highly heterogeneous disease as evidenced by the 19 subtypes and variants of large B-cell lymphoma diagnoses found in the WHO classification of tumors of hematopoietic and lymphoid tissues. However, the cancer within each patient is also characterized by heterogeneity. The fact that different lymphoma cells may co-exist in the same tumor has been known for decades. One example of this is transformation of indolent lymphoma to a more aggressive lymphoma subtype, often DLBCL where the two types of lymphoma cells are found in the same lymph node. Differences between the cancer cells in the same tumor is termed intratumor heterogeneity. Such differences may be found within the same tumor as well as at spatially separate locations(inter-tumor heterogeneity). Intratumor heterogeneity may have an important impact on the clinical course and response to therapy. In clinical practice, the prognosis in patients with similar clinical stage and International Prognostic Index (IPI) score is often diverse. Such differences may be attributed to both intra and inter-tumor heterogeneity. Molecular profiling (mutations) in different nodal and extra nodal sites within the same patient have not before been studied in larger cohorts of DLBCL patients (Inter-tumor heterogeneity).

Monitoring circulating cell-free tumor DNA (ctDNA) has the potential to serve as a non-invasive tool for measuring the entire spectrum of genetic aberrations found in an individual patient as an alternative to more invasive diagnostic procedures.

Clinical presentation of DLBCL:

DLBCL is the most common type of lymphoma, and accounts for approximately 40% of non-Hodgkin lymphomas in adults in Denmark (500 new cases per year). DLBCL can arise de novo or from the histologic transformation of more indolent lymphomas, most commonly follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). DLBCL primarily affects elderly patients with a median age at diagnosis of nearly 70 years. Patients can present with both nodal and extra-nodal involvement. More than one extra-nodal involvement is a negative prognostic factor, and some sites are associated with higher risk of having or developing CNS involvement (e.g. testis, adrenal glands, uterus).

DLBCL is characterized as a clinically heterogeneous disease with a variable outcome, however it is potentially curable. R-CHOP is the standard therapy for patients with DLBCL. The 5-year progression-free survival (PFS) is around 60%. However, more than 30% of patients treated with R-CHOP do not respond or relapse, with the majority of these patients succumbing to their disease. Despite risk models like the International Prognostic Index (IPI) and CNS-IPI, patients with a high risk of treatment failure, relapse or CNS involvement cannot be identified accurately by standard prognostic factors. Therefore, new prognostic factors and biomarkers are under investigation at diagnosis, to better identify those high-risk patients, who may benefit from an alternative therapeutic strategy.

Project aims and perspectives:

Our current understanding of the molecular mechanisms associated with DLBCL relapse is limited. It is presently unclear whether clonal heterogeneity in primary tumors plays a role in DLBCL relapse. Our study is based on the hypothesis that divergent subclones give rise to the relapse tumor in an early-divergent scenario. This scenario suggest that several divergent clones exist at diagnosis besides the one that gives rise to relapse. Thus, information regarding intratumor heterogeneity and clonal evolution of the disease may provide a better understanding of DLBCL and development of prognostic factors regarding identification of high risk DLBCL patients. If the tumor is heterogenic, as studies of ctDNA have indicated, it could potentially transform the clinical care paradigm. It could perhaps explain the diverse outcome in patients with similarly clinical presentation, or why some patients develop CNS involvement. Furthermore, knowledge of tumor heterogeneity could guide the clinician in treatment choice and protocol development and thereby improve outcome for the patients.

If heterogeneity could be detected in ctDNA it could be made operational and the patients could avoid invasive biopsy procedures. The dynamic evolution of the tumor could perhaps also be monitored by ctDNA regarding tumor burden related to interim and end of treatment PET-CT and treatment intensity.

Current genomic models in DLBCL are mainly based on single tumor biopsies. They find a wide spectrum of mutations between patients. The single tumor models may underestimate the possible heterogeneity between tumor sites in the individual patient. Furthermore, heterogeneity, data on mutational evolution and relationship with CNS involvement largely remains unknown. Our setup will make it possible to clarify heterogeneity within the individual patient and investigate the relation to prognosis and CNS involvement.

Primary objective of the study:

- To identify the pattern and variations of mutations in different lymphoma sites in individual patients

Secondary objectives:

* To identify inter-tumor heterogeneity between nodal and extra nodal sites
* To identify the association between inter-tumor heterogeneity and risk of CNS involvement
* To identify clonal evolution and clonal relationship between primary tumor site and tumor at relapse
* To explore the role of "liquid biopsies" and ctDNA in monitoring inter-tumor heterogeneity
* To identify heterogeneity between nodal sites and bone-marrow biopsy.
* Inter-patient heterogeneity identified with our local clinical lymphoma panel can be used to subdivide patients according to the Wright classification

Clinical trials:

The project will consist of a retrospective study and an observational and clinical study.

5.1 Retrospective study - cohort A - Specific markers in patients with DLBCL

The first part of the retrospective study, cohort A, will be a study of different biopsies taken from the same patient. The biopsies from different nodal and/or extra nodal sites have either been taken at the same time or at different times in the treatment course. The time period is 2015-2019.

The aim with cohort A is to explore the biopsy samples for various purposes:

* The biopsies taken at different times: give us the possibility to look at clonal evolution over time.
* The biopsies, taken at the same time, but from different sites: gives us the possibility to look at inter-tumor heterogeneity in one patient.

The results from different sites from the same patient will be compared and used to subgroup the patient according to the Wright algorithm. All analyses will be performed on paraffin embedded biopsy material.

Retrospective study - cohort B - Specific markers in patients with DLBCL and secondary CNS involvement

In the retrospective study - cohort B, the investigators explore heterogeneity and clonal evolution between CNS lymphoma and nodal/extra-nodal sites using already collected biopsies.

The investigators will look at patients with both systemic disease and involvement of the central nervous system.

The time period is: 2010-2019

The aim with cohort B is to explore the biopsy samples for various purposes:

* The biopsies, taken from different sites (CNS vs systemic) gives us the possibility to look at inter-tumor heterogeneity and possible clonal evolution.
* The biopsies taken at different times: give us the possibility to look at clonal evolution over time

By comparing our results from the retrospective cohort A, the aim is to possibly define particularly important mutations that are only present within patients whose disease has spread to the central nervous system. Knowledge of mutations that may predispose to involvement of the CNS would be essential in identifying patients with this risk.

The results from different sites from the same patient will be compared and used to subgroup the patient according to the Wright algorithm. All analyses will be performed on paraffin embedded biopsy material.

Prospective study - cohort A and B - Heterogeneity within lymphoma patients

The prospective study will include two different cohorts:

A: DLBCL patients with lymphoma involvement of several nodal sites accessible for biopsy and bone-marrow.

B: DLBCL patients with both nodal, extra-nodal sites accessible for biopsy and bone-marrow.

The prospective study will include newly diagnosed patients with DLBCL. Patients will be included in either cohort A or B according to localization of the disease ascertained by PET-CT to clarify nodal vs extra-nodal involvement.

Cohort A - patients with more than one nodal site: One additional biopsy for clinical evaluation will be performed from a different location than where the diagnostic biopsy was performed. These biopsies can explore the heterogeneity within the patient at nodal sites.

Available bone-marrow biopsies will be analyzed as a separate site.

Cohort B - patients with both nodal and extra-nodal sites: One biopsy for clinical evaluation will be performed from a different site than the diagnostic biopsy, resulting in one nodal and one extra-nodal biopsy. These biopsies will explore the heterogeneity between nodal and extra-nodal sites within the patient.

Any available bone-marrow biopsies will be analyzed as a separate site.

Biospecimens will be analyzed with next generation sequencing technique.

Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA

Differences in mutations will be analyzed with next generation sequencing

The results of next generation sequencing combined with development of CNS disease.

Differences in mutations over time will be analyzed with next generation sequencing

Explore whether the results of our ctDNA measurements can be correlated with or next generation sequencing findings from the biopsies.

Explore the possible mutational differences between these sites with next generation sequencing

Will our findings make it possible to subdivide patients into the Wright classification

Herlev Hospital

Senior Consultant

Symptoms and General Pathology

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Peripheral T-cell Lymphoma

Martina Manni, MSc, PhD

Monica Civallero, MSc, PhD

Ranjana Advani, MD

Jessica Catherine Lam, MSc, PhD

Attilio Guarini, MD

Angela Monica Sciacovelli, PhD

Maurizio Musso, MD

Emilio Ianitto, MD

Anna Marina Liberati, MD

Viviana Appolloni, PhD

Ciprian Tomuleasa, MD

Catalin Vlad, MD

Iryna Kriachok, MD

Tetiana Skrypets, MD

Massimo Federico, MD

Julie Vose, MD

Steven Horwitz, MD

Miles Prince, MD

Kim Won Seog, MD

Dolores Caballero, MD

Francesco Zaya, MD

Stefano Luminari, MD

Andrei Shustov, MD

Pierluigi Porcu, MD

Astrid Pavlovsky, MD

Carlos Chiattone, MD

Francine Foss, MD

Christopher Fox, MD

This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas.

The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL.

The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.

Peripheral T-cell non-Hodgkin lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorder arising from mature T cells of post-thymic origin at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentation. All subtypes are found more commonly in male patients, and the median age at diagnosis is 62 years. This disease is generally associated with high relapse rates and a poor prognosis, with inferior treatment outcomes compared with B-cell lymphomas and have a 5-year-survival \< 32%.

T-cell lymphomas are widely recognized as a complex and heterogeneous group of lymphoproliferative disorders, generally associated with high relapse rates and a poor prognosis. Because of their rarity, they are still very poorly understood.

The introduction of new and more effective therapies and better technologies led the International T-cell non-Hodgkin's Lymphoma Study Group to launch the T-cell Project 2.0 in order to have a contemporary, real-time understanding of the T-cell lymphoma biology and treatment, together with the application of contemporary technologies to further identification of new therapeutic targets.

Per protocol, patients are evaluated according to the treating physician's standard practice. There are no specific evaluations or visits required for the Registry. Data captured in the Registry reflects what is routinely collected for patients with PTCL.

The study plans to collect the tissue sample for central review. The ordinary fixation, cryopreservation and routine tumor cytogenetics are planned for biopsy samples. Chairmen of the Histopathology Review Panel will locate Regional sites where expert hematopathologists will review the material and perform a panel of immunostains (T-cell panel + CD20) and markers not assessed at local site.

Adding of blood sample collection will allow estimating prospectively the frequency of pEBVd detection in our cohort of PTCL patients at baseline and at the end of initial therapy, to characterize agreement between pEBVd and EBER in tumor tissue, and to explore the prognostic or predictive implications of detectable pEBVd in PTCL. Finally, to investigate the genetics and pathogenic mechanisms of aggressive PTCLs on an international scale.

Formalin-fixed tissue for central diagnostic pathology review; Peripheral blood samples.

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

We plan to share with other involved researchers the minimum information on IPD for publication.

Measured from the date of diagnosis until the date of disease progression or death from T-cell Lymphoma

Measured from the date of diagnosis until death from any cause

Measured from the date of diagnosis until the date of event

Complete response rate at 30 months (CR30) after enrollment (i.e., initiation of treatment)

Associazione Angela Serra per la ricerca sul cancro

Recurrence

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Jiachen Liu, M.D.

Jiachen Liu, master

Weiguo Zhang, Ph.D

High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence. Habitat imaging is a segmentation technique by dividing tumor regions to characterize tumor heterogeneity based on tumor pathology, blood perfusion, molecular characteristics and other tumor biological features.

In some studies, the Hemodynamic Multiparametric Tissue Signature (HTS) method has been proven to be feasible. The Hemodynamic Multiparametric Tissue Signature (HTS) consists of a set of vascular habitats obtained by Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI) of high-grade gliomas using a multiparametric unsupervised analysis method. This allowed them to automatically draw 4 reproducible vascular habitats (High-angiogenic enhancing tumor; Low-angiogenic enhancing tumor; Potentially tumor infiltrated peripheral edema; Vasogenic peripheral edema) which enable to describe the tumor vascular heterogeneity robustly.

In other studies, contrast-enhancing mass can divided into spatial habitats by K-means clustering of voxel-wise apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) values to observe the changes of voxels in spatial habitat on the time line. Using this so-called spatiotemporal habitat to identify progression or pseudoprogression in cancer therapy.

Above all, we have sufficient and firm reasons to deem that habitat imaging based on multiparametric MRI is more conducive to reflect the potential biological information inside the tumor and realize individualized diagnosis and treatment.

To sum up, the assumption of this experiment is that the Habitats Created by preoperative or postoperative Multiparametric MRI ,such as conventional MRI sequences, Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI), Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted Magnetic Resonance Imaging(DWI) ,Vessel Size Imaging (VSI) ,or Magnetic Resonance Spectroscopy (MRS) can predict the molecular mutation status, prognosis, treatment residence, progression, pseudoprogression, and even recurrence and distant intracranial recurrence in patients with high-grade gliomas.

This is a single center experiment. The subjects of this study were patients diagnosed as high-grade glioma by multiparametric magnetic resonance imaging and pathological biopsy from January 1, 2008 to December 31, 2021(or at some interval within this period). Patients meeting the inclusion criteria will enter the next experimental stage.

1. Patients selection: The patients will be clustered according to the preoperative and postoperative examination methods performed by each patient, such as only DSC sequence, both DSC and DWI sequences, or a full set of functional imaging sequences at the same time;
2. Images segmentation: To select the patients who meet the experimental design, and use deep learning-based biomedical image segmentation methods, such as Brain Tumor Segmentation (BraTS) challenge, to segment more accurate and reproducible habitats as much as possible;
3. Construction of clinical model: We may be able to obtain the parameter values of the habitat, such as CBV, ADC, Ktrans, etc. Combining these data with the basic situation of patients can build a clinical model.
4. Construction of radiomics model: The radiomics analysis will probably be structured into four parts: habitats segmentation, feature extraction, feature selection and model construction.
5. We try to analyze that habitat imaging based on Multiparametric MRI is indeed better than the conventional rough and simple ROI analysis; We try to analyze the relation between the habitats and the IDH mutation status or MGMT promoter methylation status; We try to analyze the relation between the habitats and the overall survival (OS) of the patient; We try to analyze the habitats is conducive to differentiate recurrence from distant intracranial recurrence.

Finally, statistical methods and survival analysis were used to determine whether the habitat was statistically significant for IDH mutation status and prognosis. For example, receiver operating characteristic curve (ROC) analysis evaluated the potential of the spatial habitats in IDH mutation prediction. The Kaplan-Meier curve evaluates the validation of the diagnosis in OS prediction in high-grade glioma.

How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas

To Determine Whether the Habitats Created by the Preoperative or Postoperative Multiparametric MRI Can Predict IDH Mutation Status, Prognosis, Recurrence or Intracranial Distant Recurrence of the Patients With High-grade Gliomas

The IDH status of each patient was dependent on pathological and immunohistochemical results. The overall survival for each patient is estimated since the date of operation to the end of recruitment. The overall survival will be confirmed through clinical follow-up.

Weiguo Zhang

Director of Radiology Department

Digestive System Diseases

Skin and Connective Tissue Diseases

Intestinal Diseases

Panniculitis

Julie M. Vose, MD

Emanuele Zucca, MD

Joseph M Connors, MD

Steven M. Horwitz, MD

Francine M. Foss, MD

Pier Luigi Zinzani, MD

Silvia Montoto, MD

Aaron Polliack, MD

Stefano A. Pileri, MD

Young H. Ko, MD

The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project).

It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes

Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentations. PTCLs are highly diverse, reflecting the diverse cells from which they can originate. Peripheral T-Cell Lymphomas account for 5-10% of all lymphoproliferative disorders in the Western hemisphere, with an overall incidence of 0.5-2 per 100,000 per year, and have a striking epidemiological distribution, with higher incidence in Asia.

The clinical features of PTCLs are extremely heterogeneous. PTCLs express even more clinical diversity than B-cell NHLs, and there is a close, though not absolute, relationship between some unusual clinical features and certain histological subtypes. Despite efforts to transferring to patients with T-cell lymphomas the most recent advances in the treatment of other subtypes of B-cell lymphomas, the prognosis of patients with PTCL is still poor an, unfortunately, the optimal therapy for PTCL is still unknown. The complete response rate is rather low, ranging from 40% to 50% with a median Relapse Free Survival (RFS) of 2-3 years. As a consequence of the aggressiveness of the disease and of the low efficacy of available salvage treatments, Overall Survival (OS) is also short and the long-term survival rate is lower than 10% in many series.

To better define the clinical outcome of PTCL-NOS, the Intergruppo Italiano Linfomi (IIL, now Fondazione Italiana Linfomi, FIL) performed a large study on 385 patients diagnosed and treated in the 1990s and defined a prognostic model specifically devised for patients with this uncommon disease (Gallamini, A. et al Blood, 2004. 103(7): p. 2474-9). In addition to defining a prognostic model specifically devised for PTCL-NOS, the FIL study confirms the relevance of research on series of clearly defined cases in order to the development of rationally designed and potentially more-efficacious treatment modalities. More recently, the role of biological features of the disease is emerging as an important issue not only for understanding its pathogenesis but also for prognosis and for addressing specific biologic targets altered in the neoplasia. Significant progress in the prognosis of PTCL can be expected from the novel, sophisticated, and powerful technologies of genomics and proteomics, which will allow more reliable subtyping of PTCL into distinct clinical groups characterized by different patterns of survival, as already demonstrated for some B-NHLs.

One common limitation of existing studies on prognosis of PTCL is their retrospective nature. Currently available data are based on analysis performed on series collected over a long period of time. This aspect is very important as it may introduce relevant biases in the collected series. First classification systems have changed dramatically over time and cases may have been defined in differently based on diagnosis year. Second some clinical or laboratory data which now are considered as prognostic relevant may have not been determined in older series of patients. Third in a retrospective analysis there is no guarantee that collected series are based on real consecutive cases. These are the reasons why we thought it would be useful to start a new study based on the prospective registration in a short period of time of patients with diagnosis of Peripheral T-cell lymphoma for whom it would be possible collect an exhaustive set of clinical data and biological information.

Formalin-fixed tissue for central diagnostic pathology review

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project

Preliminary analysis results will be made available during the study on the single population and separately for each subtype. Final results will be made available 6-12 months after the end of the study

Study title	NCT ID	Conditions	Eligibility	Organization
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA	NCT04763148	Lymphoma, Large...	18 Years -	Herlev Hospital
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.	NCT03964480	Peripheral T-Ce...	18 Years -	Associazione Angela Serra per la ricerca sul cancro
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas	NCT04908267	High-grade Glio...	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas	NCT04908267	High-grade Glio...	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma	NCT01142674	Lymphoma, T-Cel...	18 Years -	Associazione Angela Serra per la ricerca sul cancro
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.	NCT03964480	Peripheral T-Ce...	18 Years -	Associazione Angela Serra per la ricerca sul cancro
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.	NCT03964480	Peripheral T-Ce...	18 Years -	Associazione Angela Serra per la ricerca sul cancro
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas	NCT04908267	High-grade Glio...	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Spots Global Cancer Trial Database for heterogeneity